Table 1C.

Studies included in review.

StudyFlemming, et al17Pontikaki, et al15Actis, et al14Tarkiainen, et al13Current StudyRuemmele, et al11Quartier, et al10Wiegering,et al9Oikonomou, et al16
Publish yr2013`20062012201120162004200320102010
Study designCaseCaseCaseCaseCaseCaseObservationalCaseCase
SexMFFMMFMFMFFMNSFF
Age at IBD onset, yrs12.33228152114.812.615.2212262681117
Underlying diseaseERA JIAPoly RF-JIAOligo JIAOligo JIAJIA NOSJIA NOSERA JIAPoly RF-JIAOligo JIAPoly RF-JIARAOligo JIAOligo JIAPoly RF-JIAOligo JIA
Age at rheumatic disease onset, yrs12161.5284.399.8128562.5372
Duration of ETN treatment, yrs0.41.3NS1.52.34.42.82.17104.26014
Time from disease diagnosis to ETN start, yrsNS14.7NS13.5135.90.83.332245311
Time from ETN to IBD, yrs0.41.3NS1.52.34.42.82.17104.20014
CD/UCCDCDCDCDUCUCCDUCIDCDCDCDCDCDCD
BiopsyYYYYYYYYYYYYYYY
Concomitant treatmentMTX, PSLNSNSNSLEMTXHCQHCQ, LEFAZA, colchicineNoneSSZ, HCQPSL, AZANSNoneLEF
Decrease in IBD symptomsIBD improvedIBD improvedIBD improvedIBD improvedIBD improvedIBD persistedIBD improvedIBD persistedIBD improvedIBD improvedIBD improvedIBD improvedIBD improvedIBD improvedNS
IBD treatment afterIFXADAIFXIFXBUD, PSLSSZ, BUDMSZ, HCQMSZ, PSLADAADAADAIFXNSADAADA
IBD progression: penetrating, stricturing, inflammatoryNSNSNSNSInflammatoryNSNSNSInflammatoryStricturingMild inflam.FistulatingNSInflammatoryNS
  • IBD: inflammatory bowel disease; ETN: etanercept; CD: Crohn disease; UC: ulcerative colitis; NS: not specified; ERA: enthesitis-related arthritis; JIA: juvenile idiopathic arthritis; poly: polyarticular; RF: rheumatoid factor; oligo: oligoarticular; NOS: not otherwise specified; RA: rheumatoid arthritis; ID: undifferentiated IBD; MTX: methotrexate; PSL: prednisone; LEF: leflunomide; HCQ: hydroxychloroquine; AZA: azathioprine; SSZ: sulfasalazine; IFX: infliximab; ADA: adalimumab; BUD: budesonide; MSZ: mesalazine.